Business
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Primary endpoint met with statistically significant improvement (mean change of +2.13;
About this update from Palvella Therapeutics, Inc.
[{"type":"text","content":"Primary endpoint met with statistically significant improvement (mean change of +2.13; p","length":110,"tagName":"div"}]